Nektar Therapeutics (NKTR) Change in Acquisitions & Divestments (2010 - 2026)

Nektar Therapeutics' Change in Acquisitions & Divestments history runs 17 years deep, the most recent figure standing at $101.5 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 46.4% year-over-year to $101.5 million in Q1 2026; TTM through Mar 2026 was $316.8 million, a 11.09% increase from a year earlier, with the FY2025 full-year figure at $284.7 million, down 16.36% from the prior year.
• Change in Acquisitions & Divestments grew to $101.5 million in Q1 2026 per NKTR's latest filing, from $92.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $238.4 million in Q2 2022 and bottomed at -$626.4 million in Q4 2022.
• The 5-year median for Change in Acquisitions & Divestments is $92.0 million (2025), against an average of $42.7 million.
• Biggest YoY gain for Change in Acquisitions & Divestments was 126.34% in 2022; the steepest drop was 9789.47% in 2022.
• Year by year, Change in Acquisitions & Divestments stood at -$626.4 million in 2022, then advanced by 21.08% to -$494.4 million in 2023, then jumped by 113.17% to $65.1 million in 2024, then jumped by 41.28% to $92.0 million in 2025, then gained by 10.32% to $101.5 million in 2026.
• Per Business Quant, the three latest NKTR Change in Acquisitions & Divestments figures stand at $101.5 million (Q1 2026), $92.0 million (Q4 2025), and $54.8 million (Q3 2025).